Non-Alcoholic Fatty Liver Disease Molecular Bases, Prevention and Treatment

Nonalcoholic fatty liver disease (NAFLD) with a prevalence of 20-30% worldwide is characterized by the buildup of fat in the liver (liver steatosis) with no or little alcohol consumption. Its principal causes are modern diet and occidental lifestyle. It is characterized by metabolic disturbances suc...

Full description

Bibliographic Details
Main Author: Valenzuela, Rodrigo
Format: eBook
Language:English
Published: IntechOpen 2018
Subjects:
Online Access:
Collection: Directory of Open Access Books - Collection details see MPG.ReNa
LEADER 02121nma a2200313 u 4500
001 EB002194908
003 EBX01000000000000001332373
005 00000000000000.0
007 cr|||||||||||||||||||||
008 240202 ||| eng
020 |a 9789535140290 
020 |a 9789535139232 
020 |a 68045 
020 |a 9789535139249 
100 1 |a Valenzuela, Rodrigo 
245 0 0 |a Non-Alcoholic Fatty Liver Disease  |h Elektronische Ressource  |b Molecular Bases, Prevention and Treatment 
260 |b IntechOpen  |c 2018 
300 |a 1 electronic resource (190 p.) 
653 |a Hepatology / bicssc 
653 |a nafld, nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, obesity, mitochondria, autophagy 
700 1 |a Valenzuela, Rodrigo 
041 0 7 |a eng  |2 ISO 639-2 
989 |b DOAB  |a Directory of Open Access Books 
500 |a Creative Commons (cc), https://creativecommons.org/licenses/by/3.0/ 
024 8 |a 10.5772/68045 
856 4 2 |u https://directory.doabooks.org/handle/20.500.12854/130297  |z DOAB: description of the publication 
856 4 0 |u https://mts.intechopen.com/storage/books/6073/authors_book/authors_book.pdf  |7 0  |x Verlag  |3 Volltext 
082 0 |a 610 
520 |a Nonalcoholic fatty liver disease (NAFLD) with a prevalence of 20-30% worldwide is characterized by the buildup of fat in the liver (liver steatosis) with no or little alcohol consumption. Its principal causes are modern diet and occidental lifestyle. It is characterized by metabolic disturbances such as insulin resistance, inflammation, and oxidative stress, considered as the hepatic manifestation of metabolic syndrome. There is no effective drug therapy for this disease; therefore, lifestyle interventions remain as the first-line treatment. Nevertheless, the adherence rates to this type of treatment are very low, so great efforts are focused at finding novel therapeutic agents for the prevention of hepatic steatosis and its progression. This book presents a systematic and comprehensive revision about NAFLD, highlighting its epidemiological and molecular aspects, as well as its prevention and treatment.